Microsaic Systems Share Discussion Threads

[robste] 03/7/2018 16:27

I don't see how anyone is taking profits or making money selling at these prices. It can only be a lack of patience in the share price causing this decline. In the past MSYS seems to have attracted more than its fair share of short term investors who buy in, wait for a spike, sell and then wait for the all selling to reduce the share price so that they can buy in cheaply again. They aren't interested in long term progression, just that there are numerous and regular spikes that they can profit from. Whilst we all do this to some extent, there is a saturation point at which the sheer volume of people rushing to sell the moment the share price turns blue, actually causes a decline of the share price that it can't recover from, and the spikes stop coming. Thats what I see happening here recently. The last couple of postive RNS announcements haven't caused the expected spike and the short term investors are now moving their money elsewhere. I don't see this as a negative thing. I feel that MSYS is a medium to long term investment, and maybe when the share price inevitably starts to rise again it will do so in a much better slow and steady increase rather the up and down to stand still activity we have experienced in recent times.

[moneymunch] 03/7/2018 11:01

You're forgetting about the deal with their global biopharma partner...news could drop at anytime. Gla:-)

December 2017

Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that?

A1: Yes, absolutely so Ive got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture.

I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we'll be able to provide a lot more technical integration with the partners product.

So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can't give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales.

[kingston78] 03/7/2018 10:21

It is difficult to comprehend why a cash rich company with a great product commands a low rating and share price.

I think the answer lies with the financials. The company will need to sell a lot of its products for it to become profitable. This will not happen in the next two years.

If its invention were revolutionary its share price should rocket even if the company is loss making.

Cementing partnership and distribution agreements in different regions of the world is the first step. The company will not sell sufficient number of units unless its technology is transferred and applied in other fields.

[moneymunch] 02/7/2018 15:20

Lol, mostly in Ukog for their next stellar run, but still holding Bloc, and had a good run in GGP from 1.04p...Microsaic's turn soon. Gl ;-)

[k1ngkonggb] 02/7/2018 15:15

Didn't help with the share price The MM must be keeping it low for a reason.

Thought youre still in BLOC?

[moneymunch] 02/7/2018 14:35

Just picked up 1m plus shares in 2 trades..1.87p....Cheap as chips!!! Gla :-)

[k1ngkonggb] 25/6/2018 11:44

Expect some more disti deals

IMHO

[splatted] 25/6/2018 11:29

Great stuff!! The share price will take care of itself

[zooskeeper] 25/6/2018 10:47

Even on massive buys we hardly move

[noirua] 23/6/2018 13:49

Share price is being held back by continuing good news.

[splatted] 21/6/2018 09:12

Nicely building the groundwork here

[moneymunch] 21/6/2018 08:10

I've still got a few, and will be buying big if Bloc delivers in time. Gl ;-)

[k1ngkonggb] 21/6/2018 07:19

Thought you sold out MM?

[moneymunch] 21/6/2018 07:06

Microsaic Systems
Distribution Agreement with Amedis, spol. s ro.
RNS Number : 0483S
Microsaic Systems plc
21 June 2018


21 June 2018

Microsaic Systems plc



("Microsaic" or the "Company")



Distribution Agreement with Amedis, spol. s ro.



Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed a distribution agreement with Amedis, spol. s ro. ("Amedis"). Amedis will be the exclusive distributor of Microsaic-branded 4500 MiD® MS detectors in Slovakia.



Founded in 1991, Amedis distributes and provides application and service support for global brands across a wide range of technologies, including Liquid Chromatography Mass Spectrometry ("LCMS"), Inductively Coupled Plasma Mass Spectrometry ("ICPMS"), Gas Chromatography Mass Spectrometry ("GCMS") and Nuclear Magnetic Resonance ("NMR"). Additionally, Amedis has expertise in medical technologies, such as Linear Accelerators, Medical Imaging and Dosimetry for Radiation Therapy.



Glenn Tracey, CEO of Microsaic, commented, "Amedis is the perfect partner to distribute our compact, point of need MS technology, already having an impressive technology portfolio, unrivaled technical expertise, and full understanding of end user applications.



"Central Europe has shown impressive growth and opportunity for scientific instrumentation in recent years, and this agreement supports our growth strategy with select partners across the European region."



Milos Sebedinsky, CEO of Amedis, added: "Amedis appreciates the possibility to widen its product portfolio with the top quality Microsaic product range, especially in the field of flash chromatography purification. Our plan also is to integrate 4500 MiD® with High Performance Liquid Chromatography systems we are selling, as a complement to other detectors."

[stephen2010] 20/6/2018 09:16

UKOG about to bag again within a week :)

[k1ngkonggb] 14/6/2018 13:12

When it comes to dealing with foremost Big Pharma's, they want to be absolutely sure that any investment and commercialisation isn't tarnished by rushing things.

"In 2012, the Company started a collaboration with one of the foremost players in the global market for scientific instrumentation. Contractual development started in 2016, and Phase one (technical feasibility) was successfully completed in late 2017. Phase two (integration) was initiated in December 2017 and the Directors believe this phase will be completed in late Q4 2018. The partner provides co-development income and dedicated project resource. Subject to commercial terms being agreed, a final "commercialisation" phase ("Phase three") would follow, which the Directors estimate would last approximately 18 months, with a target completion in H1 2020."

"Having assessed potential prospects in the bioprocessing and traditional small molecule markets, the

Directors have set internal targets for 2022 of sales of approximately 390 to 450 MS instruments and

revenues of between £17 million to £19 million. The Directors have estimated that approximately 70 per cent. would come from the bioprocessing market in 2022 and the balance would come from the

Company's traditional small molecule market. The targeted revenues include recurring revenue in the form of consumables and service fee income."

[kingston78] 14/6/2018 12:23

It may take a lot of sales to make the company profitable. I think this is the problem at present. Signing partnership agreements is a big step forward but it does not guarantee actual sales.

I am disappointed that the company has not advanced its business further and faster, and its share price is languishing.

[moneymunch] 13/6/2018 07:12

13/06/2018 7:00am
UK Regulatory (RNS & others)

Microsaic (LSE:MSYS)
Intraday Stock Chart


RNS Number : 1765R

Microsaic Systems plc

13 June 2018

Microsaic Systems plc

("Microsaic" or the "Company")

Distribution Agreement with Omicron Research Ltd.

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed an agreement with Omicron Research Ltd. ("Omicron") to distribute Microsaic's 4500 MiD(R) MS detector via Omicron's distribution network in the United Kingdom.

Omicron is a UK distributor for a range of scientific instrumentation specialising in Dissolution, Chromatography and Spectroscopy, working in partnership with some of the largest scientific instrument manufacturers in the marketplace today.

Glenn Tracey, CEO of Microsaic, commented, "I am delighted to partner with one of the leading distributors of CAMAG-branded Thin Layer Chromatography ("TLC") equipment in the UK.

"TLC is a growing application area, enabling fast and simple analyses in a variety of industries, including natural products, pharmaceuticals, food and environmental. The addition of our point of need MS provides rapid compound elucidation, allowing the scientist method flexibility and simplicity with rapid diagnostic.

"Omicron is a well-established distributor of scientific instrumentation and has a strong reputation for its applications expertise and customer service.

"CAMAG is a world leader in planar chromatography. Since 1961, CAMAG has been dedicated to the development and manufacturing of instruments, software and consumables for all steps of the TLC or High-Performance Thin Layer Chromatography ("HPTLC") procedure.

"Wherever complex substance mixtures are analysed (e.g. herbal, environmental or forensic samples), TLC/HPTLC often is an excellent alternative to Gas Chromatography ("GC") and High-Performance Liquid Chromatography ("HPLC"). Moreover, it has proven value as a solid quantitative analysis technique in quality assurance of food, pharmaceuticals and other industrial products.

"Based in Muttenz, Basel, their products have an excellent reputation throughout the world."

Sam Stringer, Commercial Director of Omicron Research Ltd, added "The addition of Microsaic's innovative 4500 MiD MS detector to our product portfolio will enable Omicron to provide an exciting new opportunity to expand the analytical flexibility of TLC and HPTLC. Demand on our customers in the field of planar chromatography for further structural elucidation of their components is high, and Microsaic can provide an elegant, complementary solution to help facilitate this. Building on existing collaborations, we believe this combination of expertise and technology will be highly successful in the UK marketplace.

[timbo003] 08/6/2018 08:41

New interview with Glenn Tracey (CEO) talking about the fund raising